MeSH term
Frequency | Condition_Probility | Female | 164 | 0.0 |
Humans | 406 | 0.0 |
Pregnancy | 10 | 0.0 |
Research Support, Non-U.S. Gov't | 322 | 0.0 |
Male | 245 | 0.0 |
Microscopy, Confocal | 3 | 0.0 |
Propidium | 2 | 8.0 |
Animals | 283 | 0.0 |
Blotting, Northern | 8 | 0.0 |
Brain/*enzymology | 5 | 2.0 |
Immunohistochemistry | 93 | 0.0 |
In Situ Hybridization | 45 | 1.0 |
Postmortem Changes | 7 | 10.0 |
RNA, Messenger/analysis | 11 | 0.0 |
Rats | 154 | 1.0 |
Rats, Wistar | 27 | 2.0 |
Research Support, U.S. Gov't, P.H.S. | 196 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 3 | 0.0 |
Amygdala/metabolism | 3 | 33.0 |
Binding, Competitive/drug effects | 2 | 3.0 |
Brain/drug effects/*metabolism | 4 | 26.0 |
Hippocampus/drug effects/metabolism | 2 | 16.0 |
Ligands | 4 | 0.0 |
RNA, Messenger/metabolism | 21 | 0.0 |
Radioligand Assay | 6 | 1.0 |
Rats, Sprague-Dawley | 57 | 2.0 |
Adult | 104 | 0.0 |
Behavior, Animal/drug effects | 6 | 12.0 |
Child | 20 | 0.0 |
Cognition Disorders/chemically induced | 2 | 100.0 |
Disease Models, Animal | 31 | 1.0 |
Drug Interactions | 2 | 0.0 |
Electrophysiology | 14 | 3.0 |
Neuronal Plasticity | 4 | 14.0 |
*Prenatal Exposure Delayed Effects | 4 | 8.0 |
Synaptic Transmission/*drug effects | 2 | 12.0 |
Apoptosis/physiology | 3 | 0.0 |
Caspases/metabolism | 2 | 0.0 |
English Abstract | 16 | 0.0 |
Excitatory Amino Acid Agonists/pharmacology | 2 | 12.0 |
Hippocampus/cytology/*metabolism | 10 | 50.0 |
Kainic Acid/pharmacology | 3 | 21.0 |
Membrane Glycoproteins/metabolism | 5 | 0.0 |
Mitogen-Activated Protein Kinases/metabolism | 2 | 0.0 |
Neurons/drug effects/*metabolism | 3 | 8.0 |
Receptors, N-Methyl-D-Aspartate/metabolism | 3 | 17.0 |
Aging/metabolism | 4 | 2.0 |
Gene Expression Regulation, Developmental | 3 | 0.0 |
Hippocampus/*physiopathology | 12 | 92.0 |
Neurons/cytology/metabolism | 4 | 5.0 |
Organ Specificity | 8 | 0.0 |
Phenotype | 10 | 0.0 |
Protein Isoforms/genetics/metabolism | 2 | 1.0 |
RNA, Messenger/analysis/metabolism | 2 | 1.0 |
Aged | 120 | 0.0 |
Aged, 80 and over | 69 | 0.0 |
Analysis of Variance | 8 | 0.0 |
Case-Control Studies | 12 | 0.0 |
Cell Count/methods | 3 | 5.0 |
Comparative Study | 71 | 0.0 |
Dose-Response Relationship, Drug | 10 | 0.0 |
In Situ Hybridization/methods | 3 | 2.0 |
Middle Aged | 129 | 0.0 |
Amino Acid Sequence | 21 | 0.0 |
Blotting, Southern/methods | 2 | 7.0 |
Calcium/metabolism | 3 | 0.0 |
Cloning, Molecular | 13 | 0.0 |
Enzyme Activation | 5 | 0.0 |
Kainic Acid/*pharmacology | 5 | 38.0 |
Molecular Sequence Data | 40 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction/methods | 2 | 0.0 |
Time Factors | 33 | 0.0 |
Cercopithecus aethiops | 2 | 0.0 |
Culture Techniques | 4 | 0.0 |
Vero Cells | 2 | 0.0 |
Cell Count | 39 | 4.0 |
Maze Learning/drug effects | 2 | 22.0 |
Memory/*drug effects | 4 | 36.0 |
Cell Size | 3 | 1.0 |
Neurons/*cytology | 5 | 8.0 |
Gene Expression Regulation, Enzymologic/physiology | 2 | 2.0 |
Mice | 62 | 0.0 |
Mice, Transgenic | 11 | 0.0 |
Adolescent | 38 | 0.0 |
Astrocytes/metabolism | 2 | 2.0 |
Calcium Channels/*metabolism | 2 | 4.0 |
Dentate Gyrus/metabolism/pathology | 5 | 83.0 |
Epilepsy, Temporal Lobe/*metabolism/*pathology | 2 | 100.0 |
Hippocampus/metabolism/*pathology | 5 | 41.0 |
Immunohistochemistry/methods | 6 | 0.0 |
Sclerosis | 12 | 23.0 |
Staining and Labeling | 16 | 2.0 |
*Antigens, CD | 4 | 0.0 |
*Antigens, Neoplasm | 4 | 2.0 |
*Antigens, Surface | 4 | 5.0 |
*Avian Proteins | 4 | 4.0 |
*Blood Proteins | 4 | 5.0 |
Glial Fibrillary Acidic Protein/metabolism | 3 | 1.0 |
Oxazines/diagnostic use | 2 | 100.0 |
Mice, Knockout | 6 | 0.0 |
Synapses/pathology | 2 | 33.0 |
Neuroglia/enzymology | 2 | 33.0 |
Neurons/enzymology | 2 | 4.0 |
Oocytes/physiology | 2 | 1.0 |
*Potassium Channels, Voltage-Gated | 3 | 1.0 |
Tumor Cells, Cultured | 5 | 0.0 |
Xenopus laevis | 2 | 0.0 |
Age Factors | 14 | 0.0 |
Apoptosis | 3 | 0.0 |
Body Weight | 2 | 0.0 |
Excitatory Amino Acid Agonists/administration & dosage/*toxicity | 2 | 100.0 |
Kainic Acid/administration & dosage/*toxicity | 4 | 100.0 |
Mice, Inbred C57BL | 11 | 0.0 |
Neurons/drug effects/pathology | 3 | 30.0 |
Survival Rate | 3 | 0.0 |
Candidiasis, Oral/microbiology | 3 | 37.0 |
*DNA Fingerprinting | 5 | 11.0 |
HIV Seropositivity/*microbiology | 3 | 20.0 |
South Africa | 2 | 1.0 |
Image Processing, Computer-Assisted | 7 | 1.0 |
Neural Cell Adhesion Molecules/*metabolism | 2 | 10.0 |
Neurons/*metabolism/ultrastructure | 2 | 8.0 |
Neuropeptide Y/metabolism | 3 | 4.0 |
Somatostatin/metabolism | 3 | 6.0 |
gamma-Aminobutyric Acid/metabolism | 2 | 6.0 |
Microscopy, Electron | 9 | 0.0 |
Receptors, AMPA/*metabolism | 2 | 28.0 |
Synaptic Transmission/*physiology | 5 | 14.0 |
Aging/physiology | 3 | 1.0 |
Alzheimer Disease/genetics/*metabolism | 2 | 7.0 |
Gene Expression | 21 | 0.0 |
Nerve Tissue Proteins/genetics/metabolism | 2 | 2.0 |
RNA, Messenger/genetics/metabolism | 5 | 0.0 |
Reproducibility of Results | 2 | 0.0 |
Infant, Newborn | 10 | 0.0 |
Nerve Tissue Proteins/*genetics | 3 | 0.0 |
Pyramidal Cells/cytology/*metabolism | 2 | 40.0 |
RNA, Messenger/*metabolism | 7 | 1.0 |
Action Potentials/physiology | 3 | 6.0 |
Biological Clocks/physiology | 2 | 40.0 |
Hippocampus/cytology/*physiology | 8 | 72.0 |
Models, Neurological | 14 | 10.0 |
Neuronal Plasticity/physiology | 8 | 19.0 |
Receptors, GABA-A/metabolism | 2 | 18.0 |
*Theta Rhythm | 3 | 60.0 |
Fetus | 2 | 0.0 |
Protein Structure, Tertiary/physiology | 2 | 1.0 |
Pyramidal Cells/*metabolism/ultrastructure | 2 | 100.0 |
AIDS-Related Opportunistic Infections/*microbiology | 2 | 11.0 |
Disease Progression | 5 | 0.0 |
Candida albicans/classification/*genetics/isolation & purification | 5 | 100.0 |
DNA Fingerprinting | 13 | 11.0 |
Evolution | 3 | 0.0 |
Genotype | 6 | 0.0 |
Epilepsy, Temporal Lobe/*pathology | 5 | 62.0 |
Magnetic Resonance Imaging/*methods | 3 | 4.0 |
Sclerosis/pathology | 3 | 30.0 |
Alternative Splicing | 2 | 0.0 |
Blotting, Western | 12 | 0.0 |
Cell Line | 13 | 0.0 |
Cerebellum/*metabolism | 2 | 12.0 |
Cerebral Cortex/metabolism | 8 | 12.0 |
DNA, Complementary/metabolism | 3 | 0.0 |
Gene Library | 3 | 0.0 |
Hippocampus/*metabolism | 22 | 32.0 |
Microscopy, Fluorescence | 2 | 0.0 |
Neurons/*metabolism | 11 | 3.0 |
Sequence Homology, Amino Acid | 11 | 0.0 |
Biological Markers | 7 | 0.0 |
Kainic Acid | 11 | 68.0 |
Nerve Tissue Proteins/metabolism | 4 | 1.0 |
Rats, Inbred F344 | 4 | 1.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 38 | 0.0 |
Acetylcholine/physiology | 2 | 20.0 |
*Models, Neurological | 10 | 38.0 |
Receptors, N-Methyl-D-Aspartate/physiology | 4 | 36.0 |
Theta Rhythm | 2 | 15.0 |
Dendrites/chemistry | 2 | 50.0 |
Hippocampus/*chemistry/cytology | 4 | 80.0 |
Schizophrenia/*metabolism/pathology | 6 | 54.0 |
gamma-Aminobutyric Acid/physiology | 3 | 25.0 |
Brain/cytology/*metabolism | 3 | 6.0 |
GTP-Binding Proteins/*metabolism | 2 | 0.0 |
Neurons/cytology/*metabolism | 2 | 2.0 |
Receptors, Cell Surface/*genetics | 2 | 0.0 |
Cell Death | 8 | 2.0 |
Mice, Transgenic/genetics | 3 | 5.0 |
Neurons/pathology | 20 | 18.0 |
*Sex Characteristics | 2 | 1.0 |
Action Potentials/*physiology | 5 | 31.0 |
Memory/*physiology | 13 | 20.0 |
Nerve Net/*physiology | 4 | 33.0 |
Neurons/*physiology | 7 | 4.0 |
Brain/*metabolism | 15 | 3.0 |
DNA, Complementary/analysis/genetics | 2 | 2.0 |
Hippocampus/metabolism | 13 | 14.0 |
Phosphorylation | 5 | 0.0 |
Pyramidal Cells/metabolism | 6 | 66.0 |
Sequence Homology, Nucleic Acid | 8 | 0.0 |
Hippocampus/*metabolism/pathology/physiopathology | 2 | 66.0 |
Membrane Potentials/genetics | 2 | 22.0 |
Drug Resistance, Fungal | 2 | 28.0 |
Fluconazole/pharmacology | 3 | 21.0 |
Microbial Sensitivity Tests | 7 | 2.0 |
Mycological Typing Techniques | 3 | 30.0 |
DNA Primers | 2 | 0.0 |
Infant | 9 | 0.0 |
Lasers | 2 | 1.0 |
Polymerase Chain Reaction | 4 | 0.0 |
Kainic Acid/*toxicity | 4 | 100.0 |
Mice, Inbred BALB C | 4 | 0.0 |
Dynorphins/analysis | 2 | 100.0 |
Hippocampus/*pathology | 34 | 64.0 |
Gerbillinae | 3 | 7.0 |
Hippocampus/*drug effects/metabolism | 2 | 40.0 |
Ischemic Attack, Transient/*metabolism | 2 | 33.0 |
Microglia/drug effects/metabolism | 2 | 50.0 |
Quinolines/*pharmacology | 2 | 6.0 |
Base Sequence | 25 | 0.0 |
Phylogeny | 4 | 0.0 |
Polymorphism, Genetic | 4 | 0.0 |
Sequence Alignment | 8 | 0.0 |
Sequence Analysis, DNA | 3 | 0.0 |
Autoradiography | 42 | 8.0 |
Child, Preschool | 14 | 0.0 |
Drug Resistance | 4 | 0.0 |
Epilepsy, Temporal Lobe/*metabolism/pathology/surgery | 2 | 100.0 |
Hippocampus/*metabolism/pathology | 20 | 55.0 |
*Neuronal Plasticity | 5 | 26.0 |
Neurons/*metabolism/pathology | 7 | 12.0 |
Seizures/*chemically induced/pathology/physiopathology | 2 | 100.0 |
Status Epilepticus/chemically induced/pathology/physiopathology | 2 | 100.0 |
Synaptic Transmission/drug effects/physiology | 2 | 15.0 |
Drug Resistance, Microbial | 3 | 1.0 |
Fluconazole/therapeutic use | 2 | 14.0 |
Recurrence | 5 | 0.0 |
Behavior, Animal | 7 | 9.0 |
Gene Therapy/*methods | 2 | 0.0 |
Membrane Glycoproteins/analysis | 2 | 0.0 |
Memory | 4 | 20.0 |
Motor Activity | 3 | 6.0 |
Ion Channel Gating/*physiology | 3 | 10.0 |
Patch-Clamp Techniques | 8 | 2.0 |
Pyramidal Cells/physiology | 5 | 83.0 |
*Gene Expression | 4 | 0.0 |
Hippocampus/*cytology | 3 | 37.0 |
Astrocytes/metabolism/pathology | 3 | 11.0 |
Microglia/metabolism/pathology | 2 | 25.0 |
Pyramidal Cells/metabolism/pathology | 4 | 57.0 |
Anticonvulsants/pharmacology | 3 | 23.0 |
Epilepsy/metabolism | 2 | 28.0 |
Hippocampus/drug effects/*metabolism | 2 | 28.0 |
Neuropeptide Y/*pharmacology | 2 | 3.0 |
Alzheimer Disease/*metabolism | 17 | 8.0 |
Neurons/metabolism | 10 | 3.0 |
Alzheimer Disease/*metabolism/*pathology | 4 | 21.0 |
Hippocampus/*enzymology/*pathology | 2 | 66.0 |
Animals, Newborn | 9 | 1.0 |
Glucose/metabolism | 7 | 2.0 |
Lithium | 2 | 33.0 |
Muscarinic Agonists | 2 | 100.0 |
Pilocarpine | 5 | 62.0 |
Status Epilepticus/chemically induced/*metabolism | 3 | 100.0 |
*Brain Chemistry | 7 | 4.0 |
Mice, Inbred Strains | 3 | 0.0 |
Rabbits | 5 | 0.0 |
Cells, Cultured | 16 | 0.0 |
Electroencephalography | 12 | 4.0 |
Hippocampus/metabolism/pathology/physiopathology | 2 | 25.0 |
*Mutation | 2 | 0.0 |
Transfection | 10 | 0.0 |
Transgenes | 2 | 0.0 |
Xenopus | 2 | 0.0 |
Learning/physiology | 2 | 13.0 |
Epilepsy, Temporal Lobe/*metabolism/pathology | 3 | 60.0 |
In Vitro | 19 | 0.0 |
Receptors, GABA-B/*metabolism | 2 | 50.0 |
Apoptosis/*drug effects | 3 | 0.0 |
In Situ Nick-End Labeling | 3 | 0.0 |
Risk Factors | 2 | 0.0 |
*Computer Simulation | 4 | 5.0 |
Hippocampus/*physiology | 20 | 66.0 |
*Neural Networks (Computer) | 3 | 9.0 |
Time Perception/physiology | 2 | 50.0 |
Alzheimer Disease/*metabolism/pathology | 11 | 11.0 |
Amyloid beta-Protein/metabolism | 2 | 3.0 |
Antibody Specificity | 4 | 0.0 |
Cattle | 2 | 0.0 |
Diabetes Mellitus/*metabolism/pathology | 2 | 40.0 |
*Gene Expression Regulation, Enzymologic | 2 | 0.0 |
Glutathione/metabolism | 2 | 0.0 |
In Situ Hybridization, Fluorescence | 5 | 0.0 |
Action Potentials/drug effects | 4 | 11.0 |
Epilepsy, Temporal Lobe/physiopathology | 6 | 75.0 |
Excitatory Postsynaptic Potentials/drug effects | 3 | 75.0 |
GABA Antagonists/pharmacology | 4 | 50.0 |
Glutamic Acid/metabolism | 4 | 9.0 |
Hippocampus/cytology/drug effects/*physiology | 2 | 100.0 |
Reaction Time/drug effects | 2 | 11.0 |
Receptors, AMPA/antagonists & inhibitors | 2 | 100.0 |
Time | 2 | 6.0 |
Aging/*pathology | 5 | 19.0 |
Macaca mulatta | 8 | 1.0 |
Peptide Fragments/metabolism | 2 | 0.0 |
Tissue Distribution | 20 | 0.0 |
*Nerve Degeneration | 2 | 8.0 |
Neurofibrillary Tangles/*pathology | 4 | 18.0 |
Severity of Illness Index | 3 | 0.0 |
Hippocampus/*drug effects | 3 | 33.0 |
Excitatory Postsynaptic Potentials/drug effects/physiology | 2 | 33.0 |
Monosaccharide Transport Proteins/genetics/metabolism | 2 | 18.0 |
Neuroprotective Agents/*metabolism | 2 | 6.0 |
Acetylcholinesterase/metabolism | 2 | 2.0 |
Maze Learning/drug effects/physiology | 2 | 28.0 |
Cerebellum/cytology/metabolism | 4 | 26.0 |
Oligodendroglia/cytology/metabolism | 2 | 40.0 |
Proteins/metabolism | 2 | 0.0 |
Heat-Shock Proteins/*metabolism | 2 | 3.0 |
Hippocampus/*metabolism/*pathology | 4 | 57.0 |
Axons/*physiology | 7 | 14.0 |
Cell Survival | 5 | 0.0 |
Excitatory Amino Acid Agonists | 6 | 66.0 |
Brain Mapping | 11 | 7.0 |
Glutamic Acid/physiology | 2 | 18.0 |
Computer Simulation | 5 | 1.0 |
Entorhinal Cortex/*physiology | 2 | 66.0 |
Forecasting | 2 | 0.0 |
Nerve Net/physiology | 3 | 25.0 |
Calcium-Binding Protein, Vitamin D-Dependent/metabolism | 2 | 8.0 |
Carrier Proteins/metabolism | 4 | 0.0 |
Kainic Acid/toxicity | 6 | 75.0 |
Laterality | 2 | 3.0 |
*Membrane Transport Proteins | 4 | 0.0 |
*Organic Anion Transporters | 2 | 10.0 |
Receptors, GABA-A/*metabolism | 7 | 24.0 |
Interneurons/metabolism/pathology | 2 | 66.0 |
Neurons/metabolism/pathology | 3 | 4.0 |
Survival Analysis | 2 | 0.0 |
Neurons/*pathology | 12 | 19.0 |
Gene Expression Regulation | 3 | 0.0 |
Hippocampus/physiopathology | 3 | 37.0 |
Membrane Proteins/*genetics | 2 | 0.0 |
Drug Resistance/physiology | 2 | 8.0 |
Hippocampus/drug effects/pathology | 4 | 57.0 |
Neurons/ultrastructure | 4 | 44.0 |
Estradiol/*pharmacology | 2 | 0.0 |
Estrogen Receptor beta | 2 | 2.0 |
*Gene Expression Regulation/drug effects | 2 | 1.0 |
*Adaptor Proteins, Signal Transducing | 2 | 0.0 |
Antibodies | 6 | 1.0 |
Immunoenzyme Techniques | 13 | 0.0 |
Enzyme Inhibitors/pharmacology | 2 | 0.0 |
Indoles/pharmacology | 2 | 0.0 |
Tumor Cells, Cultured/drug effects | 3 | 0.0 |
Hippocampus/cytology/*metabolism/pathology | 3 | 75.0 |
Neurons/cytology/*metabolism/pathology | 2 | 50.0 |
Reference Values | 26 | 0.0 |
Receptors, AMPA/*analysis | 2 | 100.0 |
*Brain Mapping | 4 | 8.0 |
Energy Metabolism/*physiology | 4 | 4.0 |
Microinjections | 2 | 0.0 |
Dendrites/*pathology | 2 | 40.0 |
Microtubule-Associated Proteins/*analysis | 3 | 14.0 |
Pyramidal Cells/pathology | 5 | 50.0 |
Schizophrenia/*pathology | 6 | 46.0 |
Neurofibrillary Tangles/*chemistry | 2 | 100.0 |
Neurons/chemistry | 3 | 12.0 |
Embryo | 2 | 0.0 |
Neurons/cytology/*physiology | 3 | 9.0 |
Organ Culture Techniques | 4 | 1.0 |
Brain/metabolism/*pathology | 2 | 6.0 |
Mitochondria/*metabolism | 2 | 1.0 |
*Nerve Tissue Proteins | 3 | 0.0 |
Radioimmunoassay | 3 | 0.0 |
Cerebrovascular Circulation/physiology | 2 | 9.0 |
DNA Primers/genetics | 3 | 0.0 |
Neural Conduction/*physiology | 2 | 10.0 |
Neuronal Plasticity/*physiology | 9 | 18.0 |
Potassium Channels/*physiology | 2 | 6.0 |
Hippocampus/enzymology/*pathology | 2 | 66.0 |
Neurons/*enzymology | 4 | 5.0 |
Brain Chemistry | 4 | 1.0 |
Candida albicans/*classification/*genetics | 2 | 100.0 |
Ischemic Attack, Transient/*metabolism/pathology | 2 | 50.0 |
RNA, Messenger/genetics | 5 | 0.0 |
Recombinant Proteins/biosynthesis/chemistry | 2 | 2.0 |
*Transcription, Genetic | 3 | 0.0 |
Learning/*physiology | 3 | 15.0 |
Long-Term Potentiation/*physiology | 2 | 28.0 |
Synapses/*physiology | 4 | 11.0 |
Epilepsies, Partial/*physiopathology | 2 | 50.0 |
Seizures/*physiopathology | 3 | 27.0 |
Interneurons/pathology | 2 | 66.0 |
Neural Inhibition/physiology | 5 | 35.0 |
Pyramidal Cells/drug effects | 2 | 100.0 |
Cell Death/physiology | 4 | 5.0 |
Cerebral Cortex/injuries/metabolism/pathology | 2 | 66.0 |
Gene Expression Regulation/*physiology | 2 | 0.0 |
Glial Fibrillary Acidic Protein/analysis | 6 | 3.0 |
Maze Learning/physiology | 2 | 12.0 |
Guinea Pigs | 6 | 0.0 |
Macaca fascicularis | 4 | 1.0 |
Piperazines/pharmacology | 3 | 2.0 |
Neurons/physiology | 7 | 6.0 |
Space Perception/*physiology | 2 | 14.0 |
Excitatory Amino Acid Antagonists/pharmacology | 5 | 17.0 |
Long-Term Potentiation/drug effects/*physiology | 2 | 66.0 |
Mossy Fibers, Hippocampal/physiology | 2 | 100.0 |
Synapses/physiology | 13 | 32.0 |
Synaptic Transmission/physiology | 5 | 14.0 |
Candida albicans/*genetics | 3 | 30.0 |
Candidiasis/*microbiology | 2 | 33.0 |
Apoptosis/*physiology | 2 | 0.0 |
Immune Sera | 2 | 0.0 |
Gene Expression/physiology | 3 | 0.0 |
Neuronal Plasticity/genetics | 2 | 25.0 |
Blotting, Southern | 4 | 0.0 |
Ion Channels/physiology | 2 | 6.0 |
Limbic System/*physiopathology | 4 | 66.0 |
Receptors, GABA-A/physiology | 2 | 40.0 |
Kinetics | 8 | 0.0 |
*Membrane Proteins | 3 | 0.0 |
Epilepsy, Temporal Lobe/pathology/*physiopathology/surgery | 2 | 100.0 |
Bicuculline/pharmacology | 3 | 50.0 |
Enzyme-Linked Immunosorbent Assay | 3 | 0.0 |
Epilepsy/chemically induced/*physiopathology | 4 | 80.0 |
Sensitivity and Specificity | 3 | 0.0 |
Histocytochemistry | 13 | 1.0 |
Nerve Fibers/pathology | 2 | 8.0 |
Epilepsy, Temporal Lobe/*metabolism | 7 | 70.0 |
Synaptophysin/analysis | 2 | 5.0 |
Neurons/pathology/physiology | 2 | 25.0 |
Gene Expression Regulation/drug effects | 3 | 0.0 |
Hippocampus/drug effects/*metabolism/pathology | 2 | 100.0 |
Transcription, Genetic/*drug effects | 2 | 0.0 |
Astrocytes/pathology | 3 | 8.0 |
*Disease Models, Animal | 4 | 1.0 |
Electroencephalography/drug effects | 3 | 12.0 |
Energy Metabolism | 2 | 1.0 |
Injections | 3 | 2.0 |
Mossy Fibers, Hippocampal/pathology | 2 | 100.0 |
Silver Staining | 5 | 6.0 |
Dopamine/metabolism | 3 | 2.0 |
*Membrane Glycoproteins | 2 | 0.0 |
Receptors, N-Methyl-D-Aspartate/*metabolism | 3 | 27.0 |
Schizophrenia/*metabolism | 4 | 22.0 |
Brain Chemistry/drug effects | 2 | 12.0 |
Gene Expression/drug effects | 2 | 0.0 |
COS Cells | 2 | 0.0 |
Cytosol/metabolism | 2 | 0.0 |
Protein Biosynthesis | 2 | 0.0 |
RNA Probes | 4 | 2.0 |
*DNA Fragmentation | 2 | 10.0 |
Fluorodeoxyglucose F18/diagnostic use | 2 | 10.0 |
*Tomography, Emission-Computed | 2 | 4.0 |
Gestational Age | 4 | 0.0 |
Organ Size | 3 | 1.0 |
Aging | 4 | 1.0 |
Binding, Competitive | 7 | 0.0 |
CHO Cells | 4 | 0.0 |
Hamsters | 7 | 0.0 |
Estrogen Receptor alpha | 2 | 0.0 |
*Aging | 3 | 1.0 |
Autopsy | 12 | 6.0 |
Pyramidal Cells/*physiology | 2 | 100.0 |
DNA Fragmentation | 3 | 0.0 |
Neurons/*drug effects | 4 | 10.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Nerve Tissue Proteins/biosynthesis/*genetics | 2 | 6.0 |
Species Specificity | 14 | 0.0 |
Animals, Newborn/*physiology | 2 | 18.0 |
Brain Ischemia/*pathology | 2 | 28.0 |
Hippocampus/drug effects/physiology | 2 | 40.0 |
Serotonin/*physiology | 2 | 7.0 |
Hippocampus/metabolism/pathology | 4 | 13.0 |
Necrosis | 3 | 0.0 |
Dentate Gyrus/metabolism | 2 | 40.0 |
Macromolecular Substances | 3 | 0.0 |
RNA, Messenger/analysis/biosynthesis | 2 | 0.0 |
Dentate Gyrus/chemistry | 2 | 66.0 |
Hippocampus/*chemistry | 13 | 76.0 |
Antifungal Agents/*pharmacology/therapeutic use | 3 | 50.0 |
HIV Infections/*complications | 2 | 0.0 |
Mouth/microbiology | 3 | 23.0 |
Pharynx/microbiology | 2 | 25.0 |
Chronic Disease | 4 | 0.0 |
Multigene Family | 2 | 0.0 |
Aging/*metabolism | 9 | 4.0 |
Brain/*pathology | 3 | 1.0 |
Alzheimer Disease/*physiopathology | 3 | 15.0 |
Carbonic Anhydrases/*genetics | 6 | 23.0 |
DNA/genetics | 4 | 0.0 |
Exons | 2 | 0.0 |
*Promoter Regions (Genetics) | 2 | 0.0 |
Receptors, Neuropeptide Y/*physiology | 2 | 16.0 |
Signal Transduction | 4 | 0.0 |
Candidiasis/epidemiology/*microbiology | 2 | 66.0 |
DNA, Fungal/analysis | 5 | 25.0 |
Fluconazole/*pharmacology | 2 | 13.0 |
United States/epidemiology | 2 | 0.0 |
Cell Adhesion Molecules, Neuronal/*analysis | 2 | 25.0 |
Hippocampus/chemistry | 4 | 36.0 |
Mice, Inbred ICR | 3 | 1.0 |
*Kainic Acid | 2 | 66.0 |
Seizures/chemically induced/*physiopathology | 2 | 66.0 |
Nerve Tissue Proteins/*analysis | 4 | 5.0 |
Hippocampus/*physiology/physiopathology | 2 | 100.0 |
Mutation | 2 | 0.0 |
Nerve Fibers/physiology | 3 | 20.0 |
Restriction Mapping | 3 | 0.0 |
Entorhinal Cortex/physiology | 2 | 100.0 |
Excitatory Postsynaptic Potentials/physiology | 2 | 40.0 |
Neural Pathways/physiology | 8 | 25.0 |
Evoked Potentials/physiology | 3 | 10.0 |
Hippocampus/cytology/*drug effects/physiology | 2 | 100.0 |
Synaptic Transmission/drug effects | 3 | 11.0 |
Cognition/*physiology | 3 | 4.0 |
Tolonium Chloride | 2 | 20.0 |
Brain Chemistry/*genetics | 2 | 4.0 |
Densitometry/methods | 2 | 25.0 |
AIDS-Related Opportunistic Infections/drug therapy/*microbiology | 2 | 33.0 |
Fluconazole/*pharmacology/therapeutic use | 2 | 40.0 |
tau Proteins/metabolism | 2 | 2.0 |
Atrophy | 2 | 1.0 |
Bone Marrow Transplantation | 2 | 0.0 |
Candida albicans/*drug effects/genetics | 2 | 40.0 |
Receptors, Glutamate/analysis | 2 | 100.0 |
Binding Sites | 14 | 0.0 |
Dynorphins/*metabolism | 2 | 100.0 |
Pyrrolidines/*metabolism | 2 | 66.0 |
Tritium/diagnostic use | 4 | 3.0 |
Extracellular Space | 2 | 8.0 |
Senile Plaques/pathology | 2 | 5.0 |
Flumazenil/pharmacology | 2 | 66.0 |
Tritium | 5 | 2.0 |
Alzheimer Disease/*pathology | 7 | 13.0 |
Hippocampus/cytology/*pathology | 2 | 100.0 |
Parvalbumins/*analysis | 2 | 50.0 |
Epilepsy, Temporal Lobe/chemically induced/*metabolism/pathology | 2 | 100.0 |
Oligonucleotide Probes | 3 | 0.0 |
Seizures/metabolism/pathology | 2 | 66.0 |
Nerve Degeneration | 2 | 3.0 |
Fluorescent Dyes | 3 | 0.0 |
Epilepsy, Temporal Lobe/pathology | 2 | 100.0 |
Neurons/cytology | 3 | 6.0 |
2-Amino-5-phosphonovalerate/pharmacology | 2 | 40.0 |
Neuronal Plasticity/drug effects | 2 | 18.0 |
Swine | 3 | 0.0 |
Densitometry | 2 | 1.0 |
Laterality/physiology | 2 | 3.0 |
Ethanol/*pharmacology | 2 | 1.0 |
Electric Stimulation | 10 | 4.0 |
RNA, Messenger/biosynthesis | 3 | 0.0 |
beta-Galactosidase/metabolism | 2 | 1.0 |
Kindling (Neurology) | 3 | 42.0 |
Cerebral Cortex/cytology/metabolism | 2 | 16.0 |
Hippocampus/cytology/metabolism | 3 | 10.0 |
Hydrogen-Ion Concentration | 4 | 0.0 |
Kainic Acid/*metabolism | 2 | 66.0 |
Cell Survival/drug effects | 3 | 0.0 |
Cisplatin/pharmacokinetics/*pharmacology | 2 | 100.0 |
Heat | 2 | 0.0 |
Free Radicals | 2 | 1.0 |
Neurons/*drug effects/metabolism | 2 | 10.0 |
Nerve Tissue Proteins/analysis | 4 | 5.0 |
*Cloning, Molecular | 3 | 0.0 |
Epilepsy, Temporal Lobe/*pathology/surgery | 2 | 66.0 |
Rats, Inbred Strains | 12 | 1.0 |
Attention/*physiology | 2 | 4.0 |
Cadaver | 2 | 0.0 |
Brain/pathology | 2 | 0.0 |
Brain Edema/pathology | 2 | 50.0 |
Mouth/*microbiology | 3 | 20.0 |
Brain Chemistry/*physiology | 5 | 8.0 |
Receptors, Muscarinic/*analysis | 2 | 18.0 |
Calcium-Binding Protein, Vitamin D-Dependent/*analysis | 2 | 22.0 |
Dogs | 2 | 0.0 |
Cerebral Cortex/*metabolism | 4 | 7.0 |
Cricetulus | 2 | 0.0 |
Injections, Intraventricular | 3 | 2.0 |
Nerve Tissue Proteins/*metabolism | 5 | 1.0 |
Neurotoxins/pharmacology | 2 | 9.0 |
Neural Pathways | 2 | 11.0 |
Dizocilpine Maleate/pharmacology | 2 | 11.0 |
Cerebellum/metabolism | 5 | 12.0 |
DNA, Fungal/genetics/isolation & purification | 4 | 40.0 |
Electrophoresis | 2 | 0.0 |
Oropharynx/microbiology | 2 | 22.0 |
Variation (Genetics) | 5 | 0.0 |
Hippocampus/enzymology | 2 | 9.0 |
Amino Acid Sequence/genetics | 3 | 1.0 |
DNA Probes | 5 | 0.0 |
Vaginitis/*microbiology | 2 | 66.0 |
Neurons/*ultrastructure | 2 | 25.0 |
Microscopy, Immunoelectron | 3 | 0.0 |
Brain/metabolism | 4 | 0.0 |
Genetic Code | 2 | 4.0 |
Nerve Degeneration/physiology | 2 | 11.0 |
Alzheimer Disease/metabolism/pathology | 2 | 9.0 |
Hippocampus/*metabolism/ultrastructure | 3 | 50.0 |
RNA, Messenger/*biosynthesis | 3 | 1.0 |
Molecular Weight | 2 | 0.0 |
Protein Conformation | 2 | 0.0 |
Brain/*metabolism/pathology | 2 | 2.0 |
Carrier Proteins/*metabolism | 2 | 0.0 |
Iodine Radioisotopes | 2 | 0.0 |
Temporal Lobe/*metabolism | 2 | 33.0 |
Gene Transfer Techniques | 2 | 0.0 |
Axons/*ultrastructure | 2 | 33.0 |
Pyramidal Cells/enzymology | 2 | 50.0 |
Up-Regulation/physiology | 2 | 1.0 |
Blotting, Western/methods | 3 | 1.0 |
Candida albicans/*genetics/isolation & purification | 2 | 50.0 |
DNA, Fungal/genetics | 4 | 6.0 |
Genes, Fungal | 2 | 1.0 |
Nucleic Acid Hybridization | 14 | 0.0 |
Repetitive Sequences, Nucleic Acid | 3 | 0.0 |
Temporal Lobe/pathology | 3 | 15.0 |
Epilepsy/*physiopathology | 4 | 33.0 |
Callithrix | 2 | 2.0 |
Amphotericin B/*pharmacology | 2 | 33.0 |
Cisplatin/*pharmacology | 3 | 2.0 |
Tumor Cells, Cultured/drug effects/pathology | 2 | 4.0 |
Chromosome Mapping | 4 | 0.0 |
*Chromosomes, Human, Pair 8 | 5 | 2.0 |
Hybrid Cells | 3 | 0.0 |
Brain/*drug effects/pathology | 2 | 40.0 |
Models, Biological | 3 | 0.0 |
Models, Genetic | 2 | 0.0 |
Adenosine/analogs & derivatives/metabolism | 2 | 40.0 |
Amyloid beta-Protein/*metabolism | 2 | 2.0 |
tau Proteins/*metabolism | 3 | 6.0 |
Cats | 3 | 0.0 |
Pyramidal Tracts/physiology | 2 | 66.0 |
Hippocampus/pathology | 4 | 11.0 |
Neurofibrillary Tangles/pathology | 4 | 7.0 |
Alzheimer Disease/*enzymology/pathology | 2 | 6.0 |
Iodine Radioisotopes/diagnostic use | 2 | 0.0 |
*Kindling (Neurology) | 3 | 50.0 |
RNA, Messenger/*analysis | 2 | 0.0 |
Evoked Potentials | 3 | 5.0 |
Synaptic Transmission | 2 | 5.0 |
Brain Ischemia/*physiopathology | 4 | 25.0 |
Limbic System/physiology | 2 | 66.0 |
Hippocampus/anatomy & histology/*physiology | 4 | 80.0 |
Receptors, AMPA/physiology | 2 | 66.0 |
Seizures/physiopathology | 3 | 37.0 |
Hippocampus/*pathology/ultrastructure | 2 | 100.0 |
Macrophages/pathology | 2 | 1.0 |
Microglia/pathology | 2 | 20.0 |
Neuroglia/pathology | 2 | 9.0 |
Calcium-Binding Protein, Vitamin D-Dependent/analysis | 2 | 14.0 |
Cell Death/drug effects | 2 | 1.0 |
Hippocampus/drug effects/*pathology | 4 | 66.0 |
Injections, Intraperitoneal | 2 | 1.0 |
Seizures/*chemically induced/pathology | 2 | 100.0 |
Interleukin-6/*metabolism | 2 | 1.0 |
Deoxyribonuclease EcoRI | 2 | 4.0 |
Brain/*physiopathology | 3 | 6.0 |
RNA, Messenger/analysis/genetics/*metabolism | 2 | 33.0 |
Receptors, Nerve Growth Factor/*metabolism | 2 | 4.0 |
Action Potentials | 4 | 6.0 |
Afferent Pathways/physiology | 2 | 10.0 |
Memory/physiology | 3 | 9.0 |
Neurotransmitters/physiology | 2 | 6.0 |
Antibodies, Monoclonal | 3 | 0.0 |
Memory Disorders/*physiopathology | 2 | 66.0 |
Amino Acids/metabolism | 2 | 2.0 |
6-Cyano-7-nitroquinoxaline-2,3-dione | 2 | 50.0 |
Evoked Potentials/drug effects | 2 | 14.0 |
Membrane Potentials | 2 | 0.0 |
Acquired Immunodeficiency Syndrome/*pathology | 2 | 10.0 |
Pyramidal Tracts/pathology | 3 | 37.0 |
Nerve Fibers/*metabolism | 2 | 12.0 |
Brain/drug effects/metabolism | 2 | 7.0 |
Transcription, Genetic | 3 | 0.0 |
Calcium/*metabolism | 3 | 0.0 |
Glutamic Acid | 3 | 3.0 |
Acetylcholinesterase/*analysis | 2 | 3.0 |
Choline O-Acetyltransferase/*analysis | 2 | 7.0 |
Epilepsy, Temporal Lobe/*physiopathology | 2 | 28.0 |
Pyramidal Tracts/cytology | 2 | 100.0 |
Axons/physiology | 2 | 4.0 |
Dementia/*pathology | 2 | 14.0 |
Isoenzymes/*genetics | 3 | 0.0 |
*Multigene Family | 2 | 0.0 |
Kainic Acid/metabolism | 3 | 42.0 |
Receptors, Kainic Acid | 2 | 66.0 |
Receptors, Dopamine/*metabolism | 3 | 37.0 |
Receptors, Dopamine D2 | 2 | 13.0 |
Neurons/drug effects | 2 | 8.0 |
Axons/metabolism | 4 | 10.0 |
Limbic System/metabolism | 3 | 75.0 |
*Electroencephalography | 2 | 1.0 |
Receptors, Neurotransmitter/metabolism | 2 | 11.0 |
Receptors, Purinergic/*metabolism | 3 | 50.0 |
*Repetitive Sequences, Nucleic Acid | 3 | 0.0 |
*Chromosome Mapping | 2 | 0.0 |
Chromosome Banding | 3 | 0.0 |
Karyotyping | 3 | 0.0 |
Metaphase | 3 | 2.0 |
Hippocampus/*pathology/physiopathology | 2 | 33.0 |
Feedback | 2 | 1.0 |
Injections, Intravenous | 2 | 0.0 |
Hippocampus/analysis/*pathology | 2 | 100.0 |
Immunoblotting | 3 | 0.0 |
Hippocampus/*chemistry/metabolism/pathology | 2 | 100.0 |
Cohort Studies | 3 | 0.0 |
Haplorhini | 3 | 1.0 |
Recombination, Genetic | 2 | 0.0 |
Hippocampus/pathology/*physiopathology | 2 | 100.0 |
Oxidation-Reduction | 2 | 0.0 |
Neurotransmitters/metabolism | 2 | 5.0 |
Membrane Potentials/physiology | 2 | 2.0 |
Cell Size/physiology | 2 | 5.0 |
*Neural Inhibition | 2 | 66.0 |
Cerebrovascular Circulation | 2 | 3.0 |
Intracellular Fluid/metabolism | 2 | 1.0 |
Reaction Time | 2 | 1.0 |
Hippocampus/*anatomy & histology | 2 | 50.0 |
Cycloheximide/*pharmacology | 2 | 9.0 |
Protein Synthesis Inhibitors/*pharmacology | 2 | 6.0 |
Nuclear Proteins/metabolism | 2 | 0.0 |
Rats, Long-Evans | 2 | 4.0 |
Pilocarpine/pharmacology | 2 | 22.0 |
Diazepam/pharmacology | 2 | 11.0 |
